16 Analysts Have This To Say About Moderna
Portfolio Pulse from Benzinga Insights
16 analysts have recently evaluated Moderna (NASDAQ:MRNA), showing a mix of bullish and bearish perspectives. The average 12-month price target has decreased by 18.06% to $111.5. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Moderna faces challenges with revenue growth, net margin, ROE, and ROA, but maintains a healthy debt-to-equity ratio.
September 13, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have mixed views on Moderna, with a decrease in the average 12-month price target by 18.06% to $111.5. The company faces challenges in revenue growth and profitability, but maintains a healthy debt-to-equity ratio.
The decrease in the average price target and the lowering of ratings by several analysts indicate a negative sentiment towards Moderna's short-term stock performance. The company's financial challenges, such as declining revenue growth and poor profitability metrics, further support a bearish outlook. However, the healthy debt-to-equity ratio is a positive aspect, but it is overshadowed by the other financial difficulties.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100